BTMD
0.16 +0.055


Enter Symbol:


Enter Keyword:

LAS VEGAS, Dec 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- Mr. Keith Houser, CEO of HaloLaser Biotherapy, LLC, a Texas limited liability company, jointly announced today with Mr. Bruce Harlan, CEO of BioTech Medics, Inc. (PINK SHEETS:BTMD) (formerly Corbel Holdings, Inc.) a Nevada public corporation, that the two companies completed their reverse/merger.

Mr. Bruce Harlan, of CBLH/BTMD announced his immediate resignation as Chairman/CEO simultaneously at the time of closing of the merger. He further stated that the entire existing Board of Directors of CBLH/BTMD have resigned. Mr. Harlan said: "We are glad that the two companies have merged. HaloLaser brings proprietary assets and opportunity for growth to BioTech. BTMD begins with a new board and a new management team. We wish them and the shareholders of BTMD the very best!"

In this first press release since the merger, BioTech Medics stated that Keith Houser, age 56, is the newly elected Chairman/CEO of BioTech and that an entirely new board of directors of BioTech will be established over the next coming months. Mr. Houser declared that the new President and board member of BTMD is Charles R. Crane, M.D., age 65. Dr. Crane is a resident of Dallas, Texas, and will also be serving as Medical Director of BTMD. He has an extensive background in physical medicine and pain management, which is a major component of the new direction of the company.

Additionally, Kim Perealta Jacobs, D.C., age 41, is the newly appointed director and Secretary of BTMD. Dr. Jacobs is a chiropractor from Overland Park, Kansas. Her skills as a practicing chiropractor and acupuncturist combined with her knowledge in alternative medicine and pain management qualify her for this position.

BioTech Medics will have a new web site up and running within the next few weeks. The site is located at: www.biotechmedics.com. Background information will be available on the web site regarding all new board members, as well as product information, the company mission and goals.

Keith Houser announced that one of the first board actions will be to interview certified public accounting firms. "One key criteria for BioTech Medics to have proper standing as a reputable public company is to be an audited reporting company. Therefore, the company is anticipating the engagement of a reputable CPA firm before year end," said Mr. Houser.

Concerning the stock structure of BioTech Medics. The Board of Directors has passed a corporate resolution indicating that it has no immediate plans for any type of "reverse stock split." Mr. Houser stated: "The Board feels that the company stock structure is situated for rapid growth and we see no need to reduce or downsize the authorized capitalization of the company at this time. This should quell speculation regarding the immediate reduction in authorized shares."

Regarding those investors who hold old Corbel Holdings, Inc. (CBLH) stock certificates. The company has retained First Global Stock Transfer as the company transfer agent. The company and the transfer agent will honor old Corbel Holdings, Inc. stock certificates. A Corbel shareholder does NOT need to exchange old certificates for new at this time. However, any Corbel shareholder who desires to voluntarily request a new BioTech Medics, Inc. (BTMD) stock certificate for the old Corbel certificate may do so by contacting the company transfer agent and fully complying with the transfer requirements.

Contact information for the company transfer agent:

First Global Stock Transfer
7361 Prairie Falcon Road, Suite # 110
Las Vegas, NV 89128

Phone 702-656-4919 between 9AM-3PM-PST

The BioTech Medics Board will be addressing in specific press releases within the next few weeks what key characteristics the investor should be looking for in BioTech as an investment. Those key characteristics addressed by BTMD will include:

1. Announcements of strategic mergers, purchases and/or alliances that
will increase the company's assets (net worth), potential sales and
ultimately earnings.
2. Strategic mergers, purchases and/or alliances that will provide unique
and proprietary products and services immediately to BTMD.
3. Why and how the growth potential for BioTech Medics is excellent due to
proprietary products and services.
4. The BioTech Medics Board of Directors' goal is to register with the SEC
with audited financial statements as soon as practicable. After
implementation of the first three key characteristics of the company
specified above, and following effectiveness of its registration under
the Securities Exchange Act of 1934, the company intends to ultimately
move up to a major national stock exchange, or listing on a recognized
trading system as soon as possible.

The new corporate headquarters for BioTech Medics, Inc. will be as follows:

BioTech Medics, Inc.
222 W. Las Colinas Blvd., Suite 1650E
Irving, TX 75039 USA

Phone: 972-274-5533
Fax: 972-230-4629
Email: biotechmedics@yahoo.com

NOTE: Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to complete the planned bridge financing, market conditions, the general acceptance of the Company's products and technologies, competitive actors, timing, and other risks described in the Company's SEC reports and Filings.

SOURCE BioTech Medics, Inc.

Keith Houser, +1-972-223-2771, for BioTech Medics, Inc.

http://www.biotechmedics.com

BioTech Medics, Inc. Announces the Closing On the Medical Practice of Charles R. Crane, M.D. and Associates, Inc., Dallas, Texas, Bringing 1.2 Million Dollars of Assets Into the Company

DALLAS, Dec 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- Mr. Keith Houser, CEO of BioTech Medics, Inc. (Pink Sheets: BTMD), a Nevada public corporation announced the closing on the acquisition of the existing medical practice of Charles R. Crane, M.D. and Associates, Inc., Dallas, Texas.
"This is the first of between 75 to 100 medical practices and/or clinics the Company proposes acquiring, franchising and/or affiliating with BioTech Medics," said Mr. Houser. Our goal is to have a minimum of one or more Pain Management & Wellness Centers in each of the top 30 cities in the USA utilizing the proprietary Neurolase 150 Medical Laser device that has FDA Approval to treat "muscle, arthritic and skeletal pain." The acquisition of the medical practice of Charles R. Crane MD and Associates Inc. brings a well-established practice of over 33 years as the flagship model for other BioTech Medic's Pain Management & Wellness Centers.

Dr. Crane stated: "The practice was established in 1971 and has grown over the decades and moved from one location to another in Dallas County. Currently it is at the NorthPoint Medical Center, 12606 Greenville Avenue, Suite 105, Dallas, TX 75243. This is a very convenient Northeast Dallas location just off Interstate 635 (also known locally as LBJ Freeway) and Greenville Avenue just East past the High 5 (Highway 75 Central Expressway) interchange."

Mr. Houser indicated that the practice acquisition brings over $1.2 million in assets into BTMD, with projected gross revenues for 2005 near $1 million. Dr. Crane is a resident of Dallas, Texas, and will also be serving as Medical Director of Charles R. Crane & Associates, Inc. on behalf of BTMD. Dr. Crane is the new President of BioTech Medics. He is a Texas licensed medical doctor and is a board certified specialist in physical medicine and pain management, which is a major component of the new direction of the company.

The BioTech Medics Board will be addressing in specific press releases within the next few weeks what key characteristics the investor should be looking for in BioTech as an investment. Those key characteristics addressed by BTMD will include:

1. Announcements of Strategic mergers, purchases and/or alliances that
will increase the Company's assets (net worth), potential sales and
ultimately earnings.
2. Strategic mergers, purchases and/or alliances that will provide unique
and proprietary products and services immediately to BTMD.
3. Why and how the growth potential for BioTech Medics is excellent due
to the proprietary products and services.
4. The BioTech Medics Board of Directors' goal is to incorporate the
first three key characteristics of the Company specified above so
BTMD can ultimately move up to a major national stock exchange, or
listing as a reporting public corporation as soon as possible.